MedPath

Cytosorb Therapy in Cardiac Surgery

Completed
Conditions
Cardiopulmonary Surgery
Endocarditis
Peri-operative Cytokines Levels
Registration Number
NCT04309591
Lead Sponsor
University Hospital, Basel, Switzerland
Brief Summary

Cardiopulmonary surgery is associated with inflammatory responses that can lead to systemic inflammatory responses (SIRS), organ dysfunction (MOD) and death especially in patients with endocarditis. Cytokine removal might therefore improve outcomes of patients undergoing cardiac surgery. CytoSorb is a device designed to remove cytokine (IL-6, IL-10, TNFalpha) from the blood to reduce immune reactions. This trial investigates the use of CytoSorb during cardiac surgery in patients with endocarditis at the University Hospital Basel.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
249
Inclusion Criteria
  • patients with endocarditis undergoing cardiac surgery with cardio-pulmonary bypass circuit
Exclusion Criteria
  • denial of consent for data use

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
In-Hospital mortalityduring hospital stay for cardiac surgery from admission until discharge (approximately 15 days)

In-Hospital mortality (number of deaths) of patients with endocarditis undergoing cardiac surgery and intra-operative CytoSorb haemoadsorption

Secondary Outcome Measures
NameTimeMethod
time in intensive care unit (days)during hospital stay for cardiac surgery from admission until discharge (approximately 15 days)

time in intensive care unit (days)

In-Hospital time (days)hospital stay for cardiac surgery from admission until discharge (approximately 15 days)

In-Hospital time (days)

Trial Locations

Locations (1)

Klinik für Herzchirurgie, Universitätsspital Basel

🇨🇭

Basel, Switzerland

© Copyright 2025. All Rights Reserved by MedPath